Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
Pancreatic Cancer|Adjuvant Therapy
DRUG: Irinotecan liposome injection
Disease Free Survival, DFS, the time from the start of randomization (or the start of treatment in a one-arm trial) to the recurrence of disease or death from any cause, whichever occurs first., baseline up to approximately 21.6 months.
Adverse events (aes) were determined and graded according to NCI-CTCAE version 5.0, and evaluated by the overall incidence of AE, the incidence of AE grade 3 or above, and the incidence of SAE, Hematologic and non-hematologic adverse events during adjuvant therapy (according to NCI-CTCAE5.0);, baseline up to approximately 7 months.|Overall Survival, OS, the time from the start of randomization (or the start of treatment in a one-arm trial) to death from any cause., baseline up to approximately55 months.|Quality of life, QOL, It reflects the ability of human activities to improve the survival level and survival chances, evaluated according to EORTC Quality of life measurement scale QLQ-C30 V3.0 assessment., baseline up to approximately 55 months.|The results were presented in terms of the proportion of patients who completed 6 months of chemotherapy, The results were presented in terms of the proportion of patients who completed 6 months of chemotherapy, baseline up to approximately 7 months.|he results were presented in terms of the proportion of patients who were replaced with 5-FU/LV due to Tegafur intolerance, The results were presented in terms of the proportion of patients who completed 6 months of chemotherapy and the proportion of patients who were replaced with 5-FU/LV due to Tegafur intolerance, baseline up to approximately 7 months.
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.